Sangamo’ Positive Phase-II Results For ZFP Therapeutic Program

Sangamo has announced positive Phase-II clinical data from its ZFP Therapeutic program, to develop SB-509 as a treatment for diabetic neuropathy (DN).

Data from SB-509-601 and SB-509-701A Phase II clinical trials demonstrated that SB-509 treatment resulted in statistically significant and clinically relevant improvements in subjects with moderate and severe DN as compared to placebo. SB-509 was well-tolerated in both multi-dose studies.

Dale Ando, Vice President of Therapeutic Development and CMO at Sangamo, said: We have learned a great deal from these data, which demonstrate positive activity of SB-509 in multiple clinically relevant measurements of nerve health.

Data from our Phase 1 and both Phase 2 clinical trials have shown us that the dual angiogenic and neurotrophic effects of SB-509 are most effective in the later stages of DN when both diabetic microvascular disease and metabolic neuropathy are evident. The statistically significant improvement in SB-509-treated subjects across multiple independent clinical endpoints for DN has enabled definition of a responder group and is particularly encouraging for future trials in this patient population, he added.